Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Oct 29;10:580277. doi: 10.3389/fonc.2020.580277

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Liu, Xu, Yuan, Zhang, Zhang, Song and Yang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Representative cases of FES/FDG group. Patients with 100% of the ¹⁸F-FES positive metastatic lesions were divided into two groups by the median ratio of FES/FDG SUVmax (0.96). (A) Low FES/FDG. A 59-year-old female patient with the range of ¹⁸F-FDG and ¹⁸F-FES SUVmax was 5.3–40.7 and 4.1–15.5, respectively. This patient’s median FES/FDG was 0.52, which was lower than the median FES/FDG of all patients. She has received fulvestrant treatment for 27.6 months until progress. (B) High FES/FDG. A 67-year-old female patient with the range of ¹⁸F-FDG and ¹⁸F-FES SUVmax was 3.0–8.1 and 8.8–16.0, respectively. This patient’s median FES/FDG was 2.32, which was higher than the median FES/FDG of all patients, and the PFS was 14.7 months.